Blood · 1990 · 135 citations · 19 references
MedicineCancer BiologyOncologyMolecular OncologyNeoplasiaTumor ProgressionCentral Nervous System TumorsMalignant TumorsGanglioside CompositionNeuroblastoma Biology
Shedding of membrane gangliosides is characteristic of human and experimental tumors. Because some shed tumor gangliosides have potent tumor-enhancing properties, significant ganglioside shedding could influence tumor progression. We examined this possibility in a human tumor, neuroblastoma. Ganglioside shedding, measured as circulating tumor-derived GD2 ganglioside, and the outcome of 74 patients with advanced stage (III and IV) disease were studied. Progression-free survival (PFS) was inversely related to circulating GD2 levels at the time of diagnosis (P = .018). By Kaplan-Meier analysis, the quartile of patients having the highest circulating GD2 levels (greater than or equal to 568 pmol/mL) had a strikingly different outcome from the quartile of patients with the lowest (less than or equal to 103 pmol/mL) GD2 levels (P = .013): median PFS was shorter (9 v 28 months), and the long-term survival rate lower (2-year PFS of 24% v 70%). We conclude that more rapid disease progression and lower survival rate are associated with high circulating GD2 levels at diagnosis and speculate that shed neuroblastoma tumor gangliosides play a role in accelerating tumor progression.
19
Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients.
Gregor Schulz, David A. Cheresh, Nissi Varki et al. · PubMed · 1984 · 373 citations
Statistical estimation of prognosis for children with neuroblastoma.
Norman E. Breslow, Barbara A. McCann · PubMed · 1971 · 323 citations
Prognostic factors in neuroblastoma
Audrey E. Evans, Giulio J. D’Angio, Kathleen J. Propert et al. · Cancer · 1987 · 321 citations · Full text
Medicine, Oncology, Metastasis +9